Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC raised its stake in Savara Inc. (NASDAQ:SVRA) by 96.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 652,672 shares of the company’s stock after buying an additional 320,572 shares during the period. Renaissance Technologies LLC owned approximately 0.32% of Savara worth $3,564,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Polar Capital Holdings Plc purchased a new stake in shares of Savara during the 4th quarter worth approximately $50,086,000. RTW Investments LP acquired a new position in Savara during the fourth quarter worth $35,893,000. VR Adviser LLC boosted its position in Savara by 172.7% during the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after purchasing an additional 5,626,624 shares in the last quarter. Marshall Wace LLP purchased a new stake in Savara during the fourth quarter worth $27,496,000. Finally, Spruce Street Capital LP acquired a new stake in Savara in the fourth quarter valued at $14,539,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on SVRA. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Oppenheimer initiated coverage on shares of Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Savara currently has an average rating of “Moderate Buy” and an average target price of $10.14.

Savara Price Performance

Shares of NASDAQ:SVRA opened at $5.83 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47. The business’s fifty day moving average price is $5.62 and its two-hundred day moving average price is $5.50. The stock has a market cap of $1.19 billion, a PE ratio of -10.41 and a beta of 0.29. Savara Inc. has a one year low of $2.43 and a one year high of $7.01.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, analysts forecast that Savara Inc. will post -0.57 EPS for the current fiscal year.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.